ArticleFrontiers in immunology2026
Repetitive transcranial magnetic stimulation suppresses glia-associated neuroinflammation and promotes peripheral nerve recovery in neuropathic pain.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neuropathic pain (NP) is a chronic condition caused by peripheral nerve damage and is characterized by persistent neuroinflammation and limited treatment options. Repetitive transcranial magnetic stimulation (rTMS) has been reported to modulate neuroinflammation in the brain. However, it remains unclear whether rTMS also influences inflammatory responses in the spinal cord and peripheral nerve structures. Methods: A rat NP model was established by unilateral sciatic nerve ligation, and the effects of rTMS were evaluated through behavioral testing and molecular, histological, and ultrastructural analyses of the spinal cord and sciatic nerve. Results: NP induced thermal hyperalgesia and mechanical allodynia, whereas rTMS significantly alleviated these pain-related behaviors (p < 0.05). In the spinal cord, NP increased the expression of pro-inflammatory markers including CD40, CD86, ionized calcium-binding adapter molecule-1 (Iba-1), and transient receptor potential cation channel subfamily V member 1 (TRPV1) (p < 0.05 for TRPV1; p < 0.01 for the others). rTMS significantly attenuated the increases in CD86, Iba-1, and TRPV1 (p < 0.01 for Iba-1; p < 0.05 for the others), while CD40 showed a decreasing trend without statistical significance. In the sciatic nerve, NP also elevated glial and inflammatory markers (Iba-1, TRPV1, S100, and glial fibrillary acidic protein (GFAP), which were significantly reduced following rTMS treatment (p < 0.01 for S100; p < 0.05 for the others). Immunostaining confirmed a reduction in both the number and activation state of Iba-1(+) and GFAP(+) cells in the rTMS-treated group. Ultrastructural analysis demonstrated improved myelin integrity in the sciatic nerve after rTMS, including increased myelin thickness, higher myelinated axon density, and a reduced G-ratio. rTMS also mitigated NP-induced gastrocnemius muscle atrophy, as indicated by increased muscle mass and cross-sectional area (p < 0.01). rTMS was associated with changes in ERK and Akt signaling pathways that were reduced under NP conditions. Conclusion: rTMS alleviates NP by suppressing glia-associated neuroinflammation in both the spinal cord and sciatic nerve and by promoting structural recovery of peripheral nerves. These findings support rTMS as a promising non-invasive therapeutic strategy for NP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.